All In Biotech

Drug Trial Radar · NCT01484496

A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects With Systemic Lupus Erythematosus (SLE)

Last checked: Nov 20, 2026Latest source record: Jun 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 839 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

839

Actual

Start

Nov 16, 2011

Primary completion

Feb 13, 2015

Study completion Oct 1, 2015

Sponsor

Sponsor type
Industry
Collaborators
GlaxoSmithKline
First posted
Dec 2, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety and tolerability of belimumab administered subcutaneously (SC) to adult subjects with Systemic Lupus Erythematosus (SLE).

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • PlaceboBiological

    Placebo

  • Belimumab 200 mg SCBiological

    Belimumab 200 mg SC

  • Standard therapyDrug

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Par. Achieving a SLE Responder Index (SRI) Response Rate at Week 52Time frame: Week 52

Locations

207 sites in 31 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Peoria, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Jonesboro, Arkansas

  • GSK Investigational Site

    La Jolla, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    San Diego, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    San Leandro, California

  • GSK Investigational Site

    Tustin, California

  • GSK Investigational Site

    Upland, California

  • GSK Investigational Site

    Bridgeport, Connecticut

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Boca Raton, Florida

  • GSK Investigational Site

    Boca Raton, Florida

  • GSK Investigational Site

    Coral Gables, Florida

  • GSK Investigational Site

    Fort Lauderdale, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Orlando, Florida

  • GSK Investigational Site

    Plantation, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Duluth, Georgia

  • GSK Investigational Site

    Lawrenceville, Georgia

  • GSK Investigational Site

    Marietta, Georgia

  • GSK Investigational Site

    Boise, Idaho

  • GSK Investigational Site

    Springfield, Illinois

  • GSK Investigational Site

    Baton Rouge, Louisiana

  • GSK Investigational Site

    New Orleans, Louisiana

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Cumberland, Maryland

  • GSK Investigational Site

    Hagerstown, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Detroit, Michigan

Showing 40 of 207 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.